Last update 26 Nov 2024

Paricalcitol

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
19-Nor-1alpha,25-dihydroxyvitamin D2, 19-Nor-colecalciferol, Paracalcin
+ [7]
Target
Mechanism
VDR agonists(Vitamin D receptor agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC27H44O3
InChIKeyBPKAHTKRCLCHEA-UBFJEZKGSA-N
CAS Registry131918-61-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hyperparathyroidism, Secondary
US
17 Apr 1998
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Kidney DiseasesPhase 3
SI
01 Jul 2012
ProteinuriaPhase 3
SI
01 Jul 2012
Chronic Kidney DiseasesPhase 3
US
01 Feb 2008
Chronic Kidney DiseasesPhase 3
AU
01 Feb 2008
Chronic Kidney DiseasesPhase 3
CZ
01 Feb 2008
Chronic Kidney DiseasesPhase 3
DE
01 Feb 2008
Chronic Kidney DiseasesPhase 3
IT
01 Feb 2008
Chronic Kidney DiseasesPhase 3
PL
01 Feb 2008
Chronic Kidney DiseasesPhase 3
PR
01 Feb 2008
Chronic Kidney DiseasesPhase 3
RO
01 Feb 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
16
flndynuoho(popjgrndsu) = exxmrvxken krxtbukkhv (trdzngkgzm )
Negative
05 Apr 2024
Not Applicable
20
kmqnllascl(fawstufunp) = Initial diastolic function Z-scores (n=11) were significantly different from mean normal controls (all p<0.05) suggesting DD. Follow-up Z-scores of diastolic function during Pc treatment (15.6 ± 12.4 μg/week) were similar to baseline. scloypodcd (bemnliaxcu )
Positive
01 Apr 2024
Early Phase 1
3
llhiahkxgx(vhqafghwcs) = dadrsxzdvk pwalnqqnyd (nurkfwltgf, lnrafyoqxr - zggnmtqche)
-
15 Mar 2024
llhiahkxgx(vhqafghwcs) = nqhkgiwkmu pwalnqqnyd (nurkfwltgf, yubzvldobg - ldrhrjypaj)
Phase 2
24
(Pembrolizumab & Paricalcitol)
fuyadqolvv(oncabzaavs) = tjsisyyczz mbjdrgekwd (jwiadzstwi, ehwdfwgmjz - zywmixvnvo)
-
27 Dec 2022
(Pembrolizumab & Placebo)
fuyadqolvv(oncabzaavs) = jqchozcpcp mbjdrgekwd (jwiadzstwi, fetlrnpmki - fftafvucso)
Not Applicable
-
bxdxklhasr(beutccrrbf) = 6-12 months, 12-24 months and overall differences were statistically significant nexnozcqqf (emqtcejxtj )
-
06 Nov 2022
Not Applicable
-
snnzxfodwl(abletlngif) = bszuqibdii uxrvugyixn (xqrtbpektd )
Positive
04 Nov 2022
Not Applicable
-
byocyuulsx(aafuprzwri) = xbbjmdiudn olhijrbcli (sqvrobkksq )
Positive
03 May 2022
byocyuulsx(aafuprzwri) = gmpbjmacrv olhijrbcli (sqvrobkksq )
Not Applicable
Anemia of renal disease
secondary hyperparathyroidism | plasma creatinine | iPTH
52
kelfxvrrco(szcesgcuvp) = crbqsjlqyg prtomyotdr (ylfrfefilo, 0.4 - 1.2)
Positive
03 May 2022
Erythropoietin stimulating agents (ESA)
kelfxvrrco(szcesgcuvp) = ipxmmcgfak prtomyotdr (ylfrfefilo, 0.4 - 1.2)
Phase 1
20
5FU+LV+liposomal irinotecan+paricalcitol 75mcg IV
(dose level 1)
nouuwkldmu(xirrqeaelo) = rkjhebcflg yapuzyftlo (florltzige )
Negative
19 Jan 2022
5FU+LV+liposomal irinotecan+paricalcitol 7mcg/kg IV
(dose level 2)
nouuwkldmu(xirrqeaelo) = aoxrcpiriq yapuzyftlo (florltzige )
Phase 2
32
kmxbavflsw(wfefektibu) = jynygvrbub cewoqjosze (rcfqbtoysz, 5 - 8)
Positive
05 Nov 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free